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Edited by Vladimir SkulachevAbstract Excessive build-up of mitochondrial protonic poten-
tial is harmful to cellular homeostasis, and modulation of inner
membrane permeability a proposed countermeasure. Here, we
demonstrate that structurally distinct potassium channel open-
ers, diazoxide and pinacidil, facilitated transmembrane proton
translocation generating Hþ-selective current through planar
phospholipid membrane. Both openers depolarized mitochondria,
activated state 4 respiration and reduced oxidative phosphory-
lation, recapitulating the signature of mitochondrial uncoupling.
This eﬀect was maintained in Kþ-free conditions and shared with
the prototypic protonophore 2,4-dinitrophenol. Diazoxide, pi-
nacidil and 2,4-dinitrophenol, but not 2,4-dinitrotoluene lacking
protonophoric properties, preserved functional recovery of
ischemic heart. The identiﬁed protonophoric property of potas-
sium channel openers, thus, implicates a previously unrecognized
component in their mechanism of cardioprotection.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Coupling of aerobic oxidation with mitochondrial ATP
production proceeds through respiration-dependent genera-
tion of electrochemical Hþ gradient (DlH), the driving force of
ADP phosphorylation [1,2]. While DlH is a prerequisite for
oxidative phosphorylation, high DlH is associated with pro-
duction of reactive oxygen species, a potentially detrimental
byproduct of mitochondrial electron transfer [3,4]. Recent
ﬁndings suggest that a regulated increase in Hþ permeability of
the inner mitochondrial membrane could serve to oﬀset ex-
cessive build-up of protonic potential [5]. In fact, the inner
mitochondrial membrane harbors uncoupling proteins that
facilitate Hþ translocation and contribute to the overall reg-
ulation of proton ﬂuxes in mitochondria [6]. Genetic deletion
of uncoupling proteins produces aberrant phenotypes with* Corresponding author. Fax: +1-507-284-9111.
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doi:10.1016/j.febslet.2004.05.031augmented reactive oxygen species generation, while over-
expression reduces free radical formation and confers in-
creased protection against metabolic challenge [7–11]. These
emerging evidences implicate regulation of the mitochondrial
protonic potential in cellular tolerance to injury, yet little is
known on cytoprotective agents capable to modulate mito-
chondrial Hþ permeability.
In this regard, a class of cardioprotective potassium channel
openers, exempliﬁed by diazoxide and pinacidil, has been re-
cently shown to target and depolarize the mitochondrial inner
membrane, and to preserve mitochondrial structural and
functional integrity under stress [12–15]. Indeed, hearts treated
with these agents demonstrate a favorable energetic proﬁle
with limited damage following stress challenge [16,17]. Here,
we identify a previously unrecognized ability of potassium
channel openers to promote transmembrane Hþ-translocation
underscoring a role for protonophoric uncoupling in protec-
tion against injury.2. Materials and methods
2.1. Mitochondrial function
Intact mitochondria were isolated from pentobarbital-anesthetized
rat hearts. Respiration, membrane potential and oxidative phosphor-
ylation were measured by polarography, potentiometry and chroma-
tography, respectively, as described [18,19]. NADH-O2 oxidoreductase
activity in permeabilized mitochondria was monitored from NADH
absorbance and veriﬁed using sodium cyanide, an inhibitor of cyto-
chrome c oxidase.
2.2. Proton transfer
Proton translocation was monitored from 3H ﬂux in a Pressman’s U-
tube in the presence of charge-compensating tetraphenyl borate/ter-
tramethyl ammonia [20,21] and from Hþ-selective current across a
voltage-clamped planar phospholipid membrane [22].
2.3. Cardioprotection
Hearts isolated from anesthetized (75 mg/kg) and heparinized (500
units/animal) rats were retrogradely perfused with Krebs–Henseleit
buﬀer on a Langendorﬀ apparatus. A ﬂuid-ﬁlled balloon-tipped pres-
sure transducer (Harvard Apparatus) was used to record left ventric-
ular developed pressure [23]. Hearts were subjected to 45 min of global
non-ﬂow ischemia and re-perfused for an additional 45 min.
2.4. Drugs and chemicals
Diazoxide and pinacidil were from RBI (Natick, MA), 3H2O from
Amersham Biosciences (Piscataway, NJ), sodium tetraphenyl borate
and tertramethylammonium chloride from ICN (Costa Mesa, CA).ation of European Biochemical Societies.
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MO).
2.5. Data analysis
Data are expressed as means S.E.M. and comparison between
groups is performed using the Student’s t-test or ANOVA with a
post hoc correction procedure. A value of P < 0:05 was considered
signiﬁcant.3. Results
3.1. Potassium channel openers uncouple mitochondria
Diazoxide (100 lM; n ¼ 21) and pinacidil (100 lM; n ¼ 12)
accelerated mitochondrial state 4 respiration from 43 1 to
70 2 ng-atoms O2/min/mg protein and from 39 3 to 75 4
ng-atoms O2/min/mg protein, respectively (P < 0:05; Fig. 1A).
Concomitantly, diazoxide and pinacidil reduced mitochondrial
membrane potential (from )201 1 to )194 2 mV and from
)200 2 to )189 2 mV, P < 0:05; Fig. 1B) and diminished
ATP production (from 487 15 to 419 12 nmoles ATP/min/
mg protein and from 495 27 to 273 9 nmoles ATP/min/mg
protein, P < 0:05; Fig. 1C). In this way, potassium channel
openers recapitulated typical features of mitochondrial un-
coupling established with 2,4-dinitrophenol (5 lM), the con-
ventional mitochondrial uncoupler (Fig. 1A–C).
Opener-induced uncoupling was independent from the re-
spiratory substrate or the activity of the electron transportingFig. 1. Potassium channel openers induce mitochondrial uncoupling. (A–C) D
(5 lM, DNP) activated state 4 respiration (A), depolarized mitochondria (
succinate-supported (closed) respiration in the presence of diazoxide (D) or
oxidizing pyruvate/malate (open) or succinate (ﬁlled). (F) Eﬀect of diazoxide
mitochondria. (G–I) Maintained opener-induced activation of respiration (G)
oxidizing pyruvate/malate following KCl substitution with NaCl or LiCl.chain and required an intact mitochondrial membrane
(Fig. 1D–F). Although only diazoxide inhibited succinate ox-
idation, both openers depolarized mitochondria oxidizing ei-
ther succinate or pyruvate/malate (Fig. 1D and E insets).
Moreover, both pinacidil and diazoxide activated pyruvate/
malate supported respiration in intact mitochondria (Fig. 1D
and E), but inhibited NADH oxidation in permeabilized mi-
tochondria (Fig. 1F).
Modulation of mitochondrial Kþ permeability [24–28] was
not a prerequisite for opener-induced uncoupling. Substitution
of KCl with NaCl or LiCl partially reduced, but did not
abolish activation of respiration, mitochondrial depolarization
and reduction of ATP synthesis in the presence of diazoxide or
pinacidil (Fig. 1G–I). Diazoxide (100 lM) increased state 4
respiration by 25 3 and 21 4 ng-atoms O2/min/mg protein
in NaCl ðn ¼ 5Þ and LiCl ðn ¼ 6Þ, respectively (Fig. 1G). Pi-
nacidil (100 lM) increased respiration by 29 4 and 30 2 ng-
atoms O2/min/mg protein in NaCl ðn ¼ 6Þ and LiCl ðn ¼ 10Þ,
respectively (Fig. 1H). The depolarizing eﬀect was 7 1 and
6 1 mV for diazoxide, and 12 1 and 10 1 mV for pinacidil
(Fig. 1H), in NaCl and LiCl, respectively. ATP synthesis in
diazoxide- and pinacidil-treated mitochondria was reduced by
13% and 11% in NaCl, and by 37% and 39% in LiCl (n ¼ 3;
Fig. 1I). In contrast, valinomycin, a Kþ ionophore, lost its
ability to activate respiration, depolarize mitochondria, and
reduce ATP synthesis upon substitution of KCl with NaCl or
LiCl (not illustrated). Moreover, 5-hydroxydecanoic acidiazoxide (100 lM, DZ), pinacidil (100 lM, PN) and 2,4-dinitrophenol
B) and reduced ATP synthesis (C). (D–F) Pyruvate/malate- (open) or
pinacidil (E). Insets: Opener-induced depolarization of mitochondria
(circles) and pinacidil (triangles) on NADH oxidation in permeabilized
, membrane potential (H) and ATP synthesis (I) in intact mitochondria
Fig. 3. Protonophores protect ischemic heart. (A) Performance in
untreated (I/R), diazoxide- (DZ), pinacidil- (PN), 2,4-dinitrophenol
(DNP) or 2,4-dinitrotoluene (DNT)-treated (arrow) hearts after is-
chemia-reperfusion. (B) Post-ischemic left ventricular developed pres-
sure (LVDP) and left ventricular end-diastolic pressure (LVEDP).
Stars: P < 0:05.
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[12,13,27,28], had no eﬀect on opener-mediated uncoupling
(not illustrated). Thus, diazoxide- and pinacidil-induced mi-
tochondrial uncoupling was Kþ-independent.
3.2. Diazoxide and pinacidil are protonophores
Diazoxide (100 lM) and pinacidil (100 lM) increased 3H
ﬂux across chloroform layers, from a baseline of 2 2 3H/h/
cm2 to 10 2 and 13 2 3H/h/cm2, respectively (n ¼ 6 each,
P < 0:01), comparable to the protonophoric action of 2,4-di-
nitrophenol (Fig. 2A and B). The ability of openers to facilitate
3H transfer was further conﬁrmed by the generation of Hþ-
selective current in planar phospholipid membranes (Fig. 2C
and D). In the absence of openers, no current was recorded
across membranes separating media with diﬀerent pH
(Fig. 2C). Addition of pinacidil (Fig. 2D, n ¼ 6) and diazoxide
(not shown, n ¼ 7) induced current typical of carrier-mediated
transport [22], with a reversal potential at 52.6 0.2 mV
(Fig. 2D, n ¼ 6) and 51.5 0.1 mV ðn ¼ 7Þ, respectively. These
values closely approximate the theoretical reversal potential of
56.2 mV calculated for the utilized Hþ gradient (pH 7.02
versus 7.98 on cis and trans sides, Fig. 2C). Opener-induced
current was not observed in the absence of Hþ gradient and
showed a Hþ/Kþ selectivity >105 (not shown). Thus, pinacidil
and diazoxide facilitate Hþ transfer, thereby dissipating
transmembrane proton gradient and fulﬁlling criteria for
protonophores.Fig. 2. Potassium channel openers are protonophores. (A) Drug (X)-
facilitated diﬀusion of 3H across the chloroform-layer (dotted) sepa-
rating aqueous arms in Pressman’s U-tube. (B) 3H ﬂux in the absence
(C) and presence of diazoxide (DZ, 100 lM), pinacidil (PN, 100 lM)
or DNP (DNP, 5 lM). Stars: P < 0:05. (C) Set-up used to measure Hþ
current across planar phospholipid membranes (M) with cis and trans
sides buﬀered at diﬀerent pH (Hþcis and H
þ
trans). Reversal membrane
potential (EþH) expressed by Nernst equation; Vm – applied voltage; Rf –
feedback resistor. (D) Transmembrane current prior and following
addition of pinacidil (upward arrow). Arrowheads indicate time-points
used to determine reversal potential measured as the voltage that
nulliﬁed opener-mediated current. Opener-induced increase in trans-
membrane conductance from baseline (I ¼ 0) was determined under
continuous stirring at a given pH gradient. Voltage was held at 0 mV
except at reversal potential measurements.3.3. Protonophoric uncouplers improve cardiac recovery
Pretreatment with diazoxide, pinacidil or 2,4-dinitrophenol
promoted functional recovery and attenuated post-ischemic
contracture of hearts at reperfusion (Fig. 3A). In contrast to
poor recovery observed in the absence of drug treatment
(<10 4% of pre-ischemic levels, n ¼ 6), left ventricular de-
veloped pressure recovered to 53 12%, 68 5% and 67 17%
in diazoxide-, pinacidil- and dinitrophenol-treated hearts, re-
spectively (Fig. 3B; n ¼ 6 each). In parallel, following ische-
mia/reperfusion left ventricular end-diastolic pressure was
107 5 mmHg in untreated hearts, and was signiﬁcantly im-
proved to 51 3, 61 4 and 48 7 mmHg in diazoxide-, pi-
nacidil- and dinitrophenol-treated hearts, respectively
(Fig. 3B). In contrast, 2,4-dinitrotoluene, a chemical analog of
2,4-dinitrophenol that lacks protonophoric activity due to re-
placement of the proton-translocating hydroxyl-moiety with a
methyl group [29], did not induce myocardial protection
(Fig. 3A). In dinitrotoluene-treated hearts ðn ¼ 3Þ following
ischemia, left ventricular developed (20 5 mmHg) and left
ventricular end-diastolic (95 6 mmHg) pressures were not
signiﬁcantly diﬀerent from untreated controls (Fig. 3A and B).
Thus, cardioprotection is associated with agents that manifest
properties of protonophoric uncoupling.4. Discussion
The present study demonstrates that diazoxide and pinacidil,
two structurally distinct potassium channel openers, facilitate
proton translocation and generate Hþ-selective current across
membranes. Typical for protonophoric uncouplers, diazoxide
and pinacidil activated mitochondrial respiration, depolarized
mitochondrial membrane and reduced oxidative phosphory-
lation. Underscoring the potential beneﬁt of mitochondrial
uncoupling, potassium channel openers, along with the pro-
totypic protonophore dinitrophenol, protected ventricular
function under ischemia. Demonstrating that potassium
channel openers act as protonophores identiﬁes a novel
mechanism of action that could contribute to mitochondria-
mediated cardioprotection.
While the pharmacodynamics of potassium channel openers
could involve multiple targets, including the previously deﬁned
170 E.L. Holmuhamedov et al. / FEBS Letters 568 (2004) 167–170ATP-sensitive Kþ channels [12–15,24–28,30,31] and succinate
dehydrogenase [32,33], the present identiﬁcation of Hþ trans-
locating properties provides a possibly additional component
of their action. Diazoxide and pinacidil contain an amide or N-
cyanoguanidine moiety, respectively, that can be reversibly
protonated/deprotonated in a broad pH range [34,35] oﬀering
a physico-chemical basis for protonophoric action. Accord-
ingly, their uncoupling property mandated an intact inner
membrane with an inherently low permeability for Hþ, and
was lost following mitochondrial permeabilization. Opener-
induced uncoupling [28,36,37] was insensitive to 5-HD and was
maintained in nominally Kþ-free medium [38], in line with
recently described Kþ-independent eﬀects of potassium chan-
nel openers on free radical production under metabolic chal-
lenge [39] and maintenance of mitochondrial Ca2þ homeostasis
[40,41]. Indeed, moderate mitochondrial uncoupling prevents
excessive reactive oxygen species generation and abnormal
mitochondrial Ca2þ loading, critical events in ischemic injury
[3,10,42]. Protection aﬀorded here by diazoxide and pinacidil,
and mimicked by the mitochondrial uncoupler 2,4-dinitro-
phenol [43] could be in part associated with attenuation of
mitochondrial damage following sudden build-up of protonic
potential at reperfusion. Thus, cardioprotective potassium
channel openers act as protonophores and produce mito-
chondrial uncoupling providing a novel pharmacological
approach aimed at manipulating mitochondria-associated
functions through modulation of membrane proton
permeability.
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